Iovance Biotherapeutics Is Maintained at Buy by Goldman Sachs
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $16
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $5
Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $5
Iovance Biotherapeutics Analyst Ratings
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $18
Iovance Biotherapeutics (IOVA) Receives a Buy From Stifel Nicolaus
Jefferies Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $18
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $19
Iovance Biotherapeutics Analyst Ratings
Chardan Cuts Price Target on Iovance Biotherapeutics to $30 From $34, Keeps Buy Rating
Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $15
Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $6 to $23
Iovance Biotherapeutics Is Maintained at Outperform by Baird
Iovance Biotherapeutics (IOVA) Gets a Buy From Stifel Nicolaus